Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis.

Content Provider	Europe PMC
Author	Strosberg, Jonathan R Yao, James C Bajetta, Emilio Aout, Mounir Bakker, Bert Hainsworth, John D Ruszniewski, Philippe B Van Cutsem, Eric Öberg, Kjell Pavel, Marianne E
Copyright Year	2015
Abstract	Somatostatin analogues (SSA) have demonstrated antiproliferative activity in addition to efficacy for carcinoid symptom control in functional neuroendocrine tumors (NET). A post hoc analysis of the placebo arm of the RAD001 In Advanced Neuroendocrine Tumors-2 (RADIANT-2) study was conducted to assess the efficacy of octreotide long-acting repeatable (LAR) on progression-free survival (PFS) and overall survival (OS) estimated using the Kaplan–Meier method. Out of 213 patients randomized to placebo plus octreotide LAR in RADIANT-2, 196 patients with foregut, midgut, or hindgut NET were considered for present analysis. Of these, 41 patients were SSA-treatment naïve and 155 had received SSA therapy before study entry. For SSA-naïve patients, median PFS by adjudicated central review was 13.6 (95% CI 8.2–22.7) months. For SSA-naïve patients with midgut NET (n=24), median PFS was 22.2 (95% CI 8.3–29.5) months. For patients who had received SSA previously, the median PFS was 11.1 (95% CI 8.4–14.3) months. Among the SSA-pretreated patients who had midgut NET (n=119), the median PFS was 12.0 (95% CI 8.4–19.3) months. Median OS was 35.8 (95% CI 32.5–48.9) months for patients in the placebo plus octreotide LAR arm; 50.6 (36.4 – not reached) months for SSA-naïve patients and 33.5 (95% CI 27.5–44.7) months for those who had received prior SSA. This post hoc analysis of the placebo arm of the large phase 3 RADIANT-2 study provides data on PFS and OS among patients with progressive NET treated with octreotide therapy.
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC4609826&blobtype=pdf
ISSN	13510088
Journal	Endocrine-Related Cancer [Endocr Relat Cancer]
Volume Number	22
PubMed Central reference number	PMC4609826
Issue Number	6
PubMed reference number	26373569
e-ISSN	14796821
DOI	10.1530/erc-15-0314
Language	English
Publisher	Bioscientifica Ltd
Publisher Date	2015-09-15
Publisher Place	Bristol
Access Restriction	Open
Rights License	This work is licensed under a Creative Commons Attribution 3.0 Unported License © 2015 The authors
Subject Keyword	neuroendocrine tumors octreotide LAR progression-free survival somatostatin analogues
Content Type	Text
Resource Type	Article
Subject	Endocrinology, Diabetes and Metabolism Cancer Research Endocrinology Oncology